SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-053582
Filing Date
2024-05-06
Accepted
2024-05-06 16:20:31
Documents
49
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q oric-20240331.htm   iXBRL 10-Q 1721573
2 EX-10.1 oric-ex10_1.htm EX-10.1 46848
3 EX-10.2 oric-ex10_2.htm EX-10.2 41673
4 EX-31.1 oric-ex31_1.htm EX-31.1 15757
5 EX-31.2 oric-ex31_2.htm EX-31.2 15760
6 EX-32.1 oric-ex32_1.htm EX-32.1 8790
7 EX-32.2 oric-ex32_2.htm EX-32.2 8776
  Complete submission text file 0000950170-24-053582.txt   5827232

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT oric-20240331.xsd EX-101.SCH 779074
52 EXTRACTED XBRL INSTANCE DOCUMENT oric-20240331_htm.xml XML 838734
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

IRS No.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39269 | Film No.: 24917825
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)